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Abstract
Chronic inflammation plays a crucial role in the carcinogenesis process and, in particular, in smoking-related 
carcinogenesis. Therefore, anti-inflammatory agents provide an interesting perspective in the prevention of smoking-
associated cancers. Among nonsteroidal anti-inflammatory drugs (NSAIDs), licofelone is a triple inhibitor of both 
cyclooxygenases (COX-1 and COX-2) and of 5-lipooxygenase (5-LOX) that has shown some encouraging results in cancer 
prevention models. We previously showed that the dietary administration of licofelone, starting after weanling, to Swiss H 
mice exposed for 4 months to mainstream cigarette smoke since birth attenuated preneoplastic lesions of inflammatory 
nature in both lung and urinary tract, and had some effects on the yield of lung tumors at 7.5 months of age. The present 
study aimed at evaluating the early modulation by licofelone of pulmonary DNA and RNA alterations either in smoke-free 
or smoke-exposed H mice after 10 weeks of exposure. Licofelone protected the mice from the smoke-induced loss of body 
weight and significantly attenuated smoke-induced nucleotide alterations by decreasing the levels of bulky DNA adducts 
and 8-hydroxy-2′-deoxyguanosine in mouse lung. Moreover, the drug counteracted dysregulation by smoke of several 
pulmonary microRNAs involved in stress response, inflammation, apoptosis, and oncogene suppression. However, even 
in smoke-free mice administration of the drug had significant effects on a broad panel of microRNAs and, as assessed in 
a subset of mice used in a parallel cancer chemoprevention study, licofelone even enhanced the smoke-induced systemic 
genotoxic damage after 4 months of exposure. Therefore, caution should be paid when administering licofelone to smokers 
for long periods.
Introduction
Inhalation of mainstream cigarette smoke (MCS) is causally 
associated with cancers affecting several anatomical sites in 
humans (1) and plays an important role in the causation of a 
variety of other chronic degenerative diseases, such as chronic 
obstructive pulmonary diseases, cardiovascular diseases, and 
cerebrovascular diseases (2). The most obvious strategy to pre-
vent smoking-related diseases is to avoid exposure to MCS ei-
ther by refraining from smoking (never-smokers) or by quitting 
smoking (ex-smokers). This strategy has already proven to at-
tenuate the epidemic of lung cancer either in selected groups of 
population or in the whole male population of several countries 
in which a decrease in the consumption of cigarettes has oc-
curred (3). As a complementary approach, chemoprevention by 
means of dietary and pharmacological agents may render the 
organism more resistant to the attack of the multiple carcino-
gens contained in MCS and to interfere with carcinogenesis via 
a large variety of mechanisms (4). Besides being addressed to 
passive smokers, who are exposed to environmental cigarette 
smoke (ECS), chemoprevention targets those active smokers 
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A  further target is represented by ex-smokers, constituting a 
broad proportion of the population, who for several years have 
an increased risk to develop lung cancer compared with never-
smokers. To give an idea of the importance of chemoprevention 
in lung cancer prevention, it has been estimated that about 
234,000 new cases of lung cancer will be diagnosed in the USA 
in 2018 (5). Since the approximate latency time for lung cancer 
has been estimated to be 30 years (6), and even assuming a fur-
ther decline of lung cancer incidence in next years, this means 
that the disease has already started its course in about 7 million 
people, in whom lung cancer will be diagnosed from today to 
2049. It is a huge population in which any effort should be made 
to inhibit or to delay the growth of the neoplastic mass.
Chronic inflammation plays a crucial role among the mech-
anisms involved in the carcinogenesis process and, in par-
ticular, in smoking-related carcinogenesis (7–9). Accordingly, 
anti-inflammatory agents provide an interesting perspective 
in the prevention of smoking-associated cancers (10). In this 
context, the main mechanism of nonsteroidal anti-inflamma-
tory drugs (NSAIDs), which are among the most widely used 
drugs worldwide, is to interfere with the metabolism of ara-
chidonic acid (AA), a polyunsaturated omega-6 essential fatty 
acid (ω-6) that is the substrate for different enzyme systems. 
These include cytochromes P450 (CYP), lipoxygenases (LOX), 
and cyclooxygenases (COX), which catalyze arachidonic acid 
oxygenation thereby generating prostaglandin endoperoxides 
(PGE). In addition, NSAIDs may reduce the ‘inflammogenesis of 
cancer’ by lowering the levels of inflammation mediators, such 
as cytokines, chemochines, and adhesion molecules that are in-
volved in airway and pulmonary diseases (11–13). While COX-1 
is the housekeeping isoform, the PGEs derived from COX-1 being 
involved in the homeostatic maintenance of the gastric mucosa, 
COX-2 is the inducible isoform, which is expressed in response 
to certain stimuli such as mitogens, cytokines and growth fac-
tors having a pro-inflammatory function (14). Arachidonic acid 
is metabolized by 5-LOX to leukotrienes (LTEs), one of which 
(LTE-B4) has been shown to be involved in the development of 
gastrointestinal ulcers (15). Increased levels of urinary PGE-M 
and LTE (4) were found in human smokers, a result that may 
reflect subclinical lung inflammation, and administration of the 
selective COX-2 inhibitor celecoxib shunted arachidonic acid 
into the proinflammatory 5-LOX pathway. Since 5-LOX activity 
and LTE (4) play a role in cardiovascular disease, these results 
may help to explain the link between use of COX-2 inhibitors 
and cardiovascular complications (16). Thus, targeting COX and 
5-LOX pathways may provide better efficacy without unwanted 
cardiovascular and gastrointestinal side effects (17).
Using a murine model of MCS-related carcinogenesis, we 
previously investigated the ability of a variety of pharma-
cological agents to modulate the yield of lung tumors and 
other histopathological alterations [see a review in ref. (18)]. 
Among anti-inflammatory drugs, we investigated the cancer-
prevention ability of 4 NSAIDs, including the selective COX-2 
inhibitor celecoxib (19), the COX-1 and COX-2 inhibitors aspirin 
and naproxen (20), and the triple COX-1, COX-2, and 5-LOX in-
hibitor licofelone (19). In addition, we evaluated the properties 
of celecoxib (21), naproxen and aspirin (22) to modulate MCS-
related alterations of genomic and epigenetic nature in mice.
Licofelone (2-[6-(4-chlorophenyl)2,2-dimethyl-7-phenyl-
2,3-dihydro-1H-pyrrolizin-5-yl]acetic acid, CAS 156897-06-2), 
a triple inhibitor of both COXs and 5-LOX, has been proposed 
as a new tool in anti-inflammatory therapy (23), particularly 
in the treatment of osteoarthritis (24). In addition, both COXs 
and 5-LOX have been implicated in carcinogenesis and espe-
cially in colon carcinogenesis, and the striking interrelation-
ship of their biological functions suggests that molecules that 
are able to block both COX-2 and 5-LOX pathways may provide 
a promising approach to colon cancer prevention (17). Using 
experimental test systems, licofelone was found to inhibit the 
formation of tumors, such as spontaneous intestinal tumors 
in APCMin/+ mice (17,25) and spontaneous urothelial cell car-
cinoma growth and invasion in UPII-SV40T transgenic mice (26), 
squamous cell carcinomas of the tongue in male F344 rats re-
ceiving 4-nitroquinoline-1-oxide in the drinking water (27), and 
lung adenomas induced by benzo[a]pyrene in female A/J mice 
receiving licofelone via oropharyngeal aspiration (28). In add-
ition, especially when combined with the epidermal growth 
factor receptor (EGFR) inhibitor gefinitib, licofelone inhibited 
the incidence of pancreatic intraepithelial neoplasms and their 
progression to pancreatic ductal adenocarcinoma using p48Cre/+-
LSL-KrasG12D/+ mice expressing the activated KrasG12D oncogene 
(29). In that model, miRNAs characteristics of pancreatic tumor-
initiating/cancer stem cells and inflammation were modulated 
by this NSAID (30). Licofelone also inhibited the formation of 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced 
lung tumors in A/J mice, an effect that was potentiated by 
the simultaneous administration of difluoromethylornithine 
(DFMO) (31).
 We previously demonstrated that the dietary administra-
tion of licofelone, starting after weanling, to Swiss H mice of 
both genders exposed for 4 months to MCS since birth attenu-
ated preneoplastic lesions of inflammatory nature in both lung 
and urinary tract, and had some effects on the yield of lung tu-
mors at 7.5 months of age (19). We report herein the results of 
an independent study in which we evaluated, under the same 
experimental conditions, the early modulation by licofelone of 
pulmonary DNA and RNA alterations either in smoke-free or 
MCS-exposed mice after 10 weeks of exposure. Nucleotide alter-
ations were investigated by measuring bulky DNA adducts and 
8-hydroxy-2′-deoxyguanosine (8-oxodGuo), and RNA alterations 
were evaluated by determining the expression of 1,135 mouse 
microRNAs (miRNAs). The results obtained show that licofelone 
is able to significantly attenuate MCS-induced DNA alterations 
Abbreviations:  
AA arachidonic acid; 
COX cyclooxygenase; 
CYP cytochrome P450; 
DFMO difluoromethylornithine; 
DRZ diagonal radioactive zone; 
ECS environmental cigarette smoke; 
EGFR epidermal growth factor receptor; 
HCA hierarchical cluster analysis; 
LTE leukotriene; 
LOX lipooxygenase; 
MCS mainstream cigarette smoke
miRNA microRNA; 
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in mouse lung and to counteract dysregulation by MCS of sev-
eral miRNAs. However, in smoke-free mice, administration of 
the drug had significant effects on an even broader panel of 
miRNAs and, as assessed in a subset of mice used in the cancer 
chemoprevention study (19), licofelone even enhanced the MCS-
induced systemic genotoxic damage after 4 months of exposure.
Materials and methods
Mice
Strain H mice, originated from Swiss albino mice, were used. These mice 
are sensitive to the induction of preneoplastic and neoplastic lung alter-
ations induced by MCS (32). The mice were originated and bred in the 
Animal Laboratory of the National Center of Oncology (Sofia, Bulgaria) 
and shipped to the Department of Health Sciences at the University of 
Genoa (Italy), where they were housed in Makrolon™ cages, maintained 
on standard rodent chow (Teklad 2018, Harlan Laboratories, San Pietro al 
Natisone, Udine, Italy), and given drinking water ad libitum. The animal 
room temperature was 23 ± 2°C, with a relative humidity of 55% and a 12 h 
day–night cycle. Housing and treatments of mice were in accordance with 
European (2010/63 UE Directive) and institutional guidelines. The issuance 
of the Office of Laboratory Animal Welfare (OLAW) with the University of 
Genoa bears the identification number A5899-01 and is effective until 28 
February 2021.
Exposure to MCS
A whole-body exposure of mice to MCS was carried out as previously 
described (32), by using 3R4F Kentucky reference cigarettes (College of 
Agriculture, The Reference Cigarette Program, University of Kentucky, 
Lexington, KY, USA), having a declared content of 9.4 mg tar and 0.73 mg 
nicotine, and delivering 12  mg of CO each when burned. MCS was de-
livered to the exposure chambers by drawing 15 consecutive puffs, each 
of 60 ml and lasting 6 s. Each daily session involved 6 consecutive expos-
ures, lasting 10 min each, with 1 min intervals during which a total air 
change was made in order to avoid sufferance of mice. Exposure started 
within 12 h after birth and continued daily until the end of the experiment 
(10 weeks). The average total particulate matter in the exposure chambers 
was 684 mg/m3.
Licofelone
Licofelone was supplied by the US NCI via MRIGlobal (Kansas City, MO, 
USA). As previously reported (19), a subchronic toxicity study was carried 
out in H mice by incorporating the drug in the diet at the doses of 150, 
300, 600 and 1200 mg/kg. These doses were selected based on literature 
data relative to experimental studies in mice and by taking into account 
the therapeutic doses used in humans. At any licofelone dose, neither 
sufferance nor alterations in the behavior of mice were detected at daily 
inspections nor the body weight gain was affected by more than 10% as 
compared with controls. Therefore, the 80% of the highest tested dose, cor-
responding to 960 mg licofelone/kg diet, was used in the chemoprevention 
study.
Chemoprevention study
This study used a total of 40 neonatal mice, which were divided into the 
following 4 groups, each composed of 5 males and 5 females: Group 1. Mice 
kept in filtered air (sham-exposed mice); Group 2. Mice receiving licofelone 
with the diet after weanling (licofelone-treated mice); Group 3. Mice ex-
posed to MCS since birth (MCS-exposed mice); Group 4. Mice exposed to 
MCS since birth and receiving licofelone with the diet after weaning (MCS-
exposed mice treated with licofelone). At 10 weeks of age, i.e. 6 weeks after 
weaning, all mice were sacrificed and their lungs were collected. The right 
lung of each mouse was immersed in RNAlater® solution for 24 h and then 
transferred at −80°C until RNA extraction and analysis. The left lung was 
directly transferred at −80°C until DNA extraction and analysis.
Extraction and analysis of lung DNA
As previously described (33), DNA was extracted from tissue speci-
mens (50 mg) collected individually from the left lungs of 40 mice. The 
specimens were homogenized by using a tissue lyser (TissueLyser, Qiagen,, 
Gaithersburg, MD, USA) and, after centrifugation at 14 000 × g at 4°C for 
15 min, DNA was purified from the supernatant by using a commercially 
available kit (GenElutt™ Mammalian Genomic DNA Miniprep kit, Sigma, 
St Louis, MO, USA). Spectrophotometric analyses by means of a fiber optic 
spectrophotometer (Nanodrop ND-1000, Thermo Scientific, Wilmington, 
DE, USA) showed a satisfactory quality of the DNA extracted from the 40 
processed samples, with an average 260/280 ratio of 1.9 ± 0.01 (mean ± SE). 
Bulky DNA adducts, after butanol enrichment, and 8-oxodGuo were meas-
ured by 32P postlabeling procedures as previously described (34).
Modulation of the systemic MCS genotoxicity
Modulation by licofelone of the systemic MCS genotoxicity was evaluated 
in a subset of mice used in a parallel cancer chemoprevention study (19). 
At 4  months of age, immediately after discontinuing exposure to MCS, 
peripheral blood was collected from the tail lateral vein and smeared onto 
slides (2 slides/mouse) from 20 mice (10 males and 10 females) per each 
one of the experimental groups, including (a) sham-exposed mice, (b) 
MCS-exposed mice in the absence of the chemopreventive agent and (c) 
MCS-exposed mice receiving licofelone with the diet after weaning. After 
staining of blood smears with May–Grünwald–Giemsa, the frequency of 
micronucleated normochromatic erythrocytes (MN NCE) was scored by 
analyzing microscopically 50 000 NCE/mouse.
Extraction and analysis of lung RNA and expression 
of miRNAs
For RNA extraction, fragments (10 mg each) of right lungs were homogen-
ized in QIAzol Lysis Reagent by continuous shaking in Tissue Lyser (Qiagen 
Hilden, Germany). After centrifugation at 14 000 × g at 4°C for 15 min, RNA 
was purified by using a commercially available kit (miRNeasy, Qiagen). 
Spectrophotometric analyses by fiber optic spectrophotometer (Nanodrop 
ND-1000) indicated a satisfactory quality of the RNA extracted from all 
samples, with an average 260/280 ratio of 2.1 ± 0.16 (mean ± SE). The RNA 
structural integrity was evaluated by capillary electrophoresis using a 
RNA bioanalyzer (Bioanalyzer Agilent 2100, Agilent Santa Clara, CA, USA) 
equipped with a RNA oligonucleotide chip (RNA 6000 Nano Ladder Chip, 
Agilent). The RNA Integrity Number (RIN), which is obtained by calculating 
the ratio between ribosomal RNA bands and total RNA, was 6.5  ± 0.21 
(mean ± SE). The specimens collected from all experimental groups were 
processed as two pools composed of 5 mice each, one for males and the 
other one for females.
The expression of pulmonary miRNAs was evaluated by using the 
seventh-generation miRCURY LNA™ microRNA Array (Exiqon), which 
contains 3100 capture probes covering human, mouse and rat miRNAs. 
In particular, this array covers 1135 mouse miRNAs, which correspond to 
the 88.6% of the 1281 mouse miRNAs listed in miRBase 19. miRNA micro-
array expression data have been recorded in GEO database (GEO accession 
number requested).
For miR-30b, microarray results in the four experimental groups were 
validated by qPCR. The standard qPCR SYBR green procedure was used, as 
described elsewhere (22). Four replicates of each sample were analyzed.
Statistical analysis
The differences among the experimental groups relative to body weights, 
frequency of MN NCE, and levels of pulmonary DNA adducts and 8-oxo-
dGuo, all of them expressed as means ± SE within each group of mice, were 
evaluated for statistical significance by ANOVA followed by Student’s t test 
for unpaired data. miRNA microarray data were analyzed by GeneSpring 
software (Agilent, Santa Clara, CA, USA) after local background subtrac-
tion, log transformation and normalization, and expression data were 
median centered by using the GeneSpring normalization option. The 
overall treatment-related variability of microarray data was evaluated by 
scatter-plot analysis (SPA), hierarchical cluster analysis (HCA), sprincipal 
component analysis (PCA) and volcano-plot analysis (VPA). The statistical 
significance of the differences among experimental groups was evaluated 
by means of the GeneSpring ANOVA by using Bonferroni multiple testing 
correction. Differences between sets of data, inferred from volcano-plot 
analysis, were taken as significant when they showed at least a 2-fold vari-
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Results
Licofelone does not affect survival and protects 
the mice from the slight MCS-induced loss of body 
weight gain
All the 40 mice used for the evaluation of nucleotide modifi-
cations and microRNA expression survived throughout dur-
ation of the experiment. Supplementary Table S1, available at 
Carcinogenesis Online, shows the body weights of these mice, 
which were measured at weekly intervals after weaning until 
the end of the experiment. Exposure to MCS, starting soon after 
birth, resulted in a slight decrease of body weight gain in both 
males and females. Such a body weight loss was moderate but 
statistically significant in males from week 3 after weaning, 
i.e. approximately at 7 weeks of life, and in females from week 
4 onwards, i.e. at 8 weeks of life. In any case, the maximum 
body weight loss in MCS-exposed mice, compared with sham-
exposed mice, was the 15.3% in males and the 7.9% in females. 
Administration of licofelone did not affect the body weight gain 
in smoke-free mice, whereas the drug exerted some protection 
in MCS-exposed mice. In fact, in MCS-exposed females treated 
with licofelone there was no significant difference, at any time, 
compared with sham-exposed females. In MCS-exposed males 
treated with licofelone there was a complete recovery after 6 
weeks, when the body weight was significantly higher as com-
pared with MCS-exposed mice in the absence of the drug.
Licofelone inhibits the MCS-induced formation of 
bulky DNA adducts in lung
Exposure of mice to MCS resulted, at 32P postlabeling, in the for-
mation of a diagonal radioactive zone (DRZ, Figure 1). Table 1 (left 
column) summarizes the results of the analysis of bulky DNA 
adducts in the lung of 40 mice. On an average, MCS increased 
DNA adduct levels 13.7-fold in males and 16.3-fold in females. 
Licofelone did not affect DNA adduct levels in smoke-free mice 
but significantly attenuated the increase induced by MCS both 
in males, with a 2.1-fold decrease, and in females, with a 2.0-fold 
decrease. Inhibition of MCS-related DNA adducts by licofelone 
mainly affected slowly migrating components of DRZ (Figure 1).
Licofelone inhibits the MCS-induced oxidative DNA 
damage in lung
As shown in Table 1 (right column), exposure of mice to MCS 
caused oxidative DNA damage in the lung, with a 3.0-fold in-
crease of 8-oxo-dGuo in males and a 2.8-fold increase in fe-
males. Administration of licofelone, which per se did not affect 
8-oxo-dGuo levels in smoke-free mice, significantly attenuated 
the MCS-related oxidative DNA damage, with a 3.0-fold decrease 
in males and a 2.8-fold decrease in females. Thus, the values 
recorded in MCS-exposed mice treated with licofelone were 
comparable to the 8-oxo-dGuo levels observed in sham-exposed 
mice.
Licofelone causes a late increase of systemic 
genotoxic damage in MCS-exposed mice
The frequency of MN NCE was evaluated in the peripheral blood 
of 60 mice aged 4  months, immediately after discontinuation 
of exposure to MCS and after 3  months of administration of 
licofelone. These mice were a subset of the mice used in a par-
allel cancer prevention study (19). As shown in Table 2, exposure 
to MCS of both male and female mice resulted in a small but sig-
nificant increase in MN NCE frequency, as compared with sham-
exposed mice. Administration of licofelone to MCS-exposed 
mice caused a further significant increase in MN NCE frequency 
in both males and females, when compared with MCS-exposed 
mice in the absence of chemopreventive agent.
Licofelone dysregulates a number of pulmonary 
miRNAs while counteracting MCS-related alterations
Initially, we performed separate analyses of microarray data for 
males and females (data not shown). Since no gender differences 
were detected, we decided to merge the results for males and 
females in order to analyze larger numbers of mice per group. 
HCA (Figure 2A) showed that Sham and MCS are located in op-
posite branches of the dendrogram. Licofelone alone is linked 
with Sham, and MCS + licofelone has an intermediate position, 
being located in a different branch compared with MCS in the 
absence of drug. In bidimensional PCA (Figure 2B), licofelone 
and Sham fell in the same quadrant, whereas MCS + licofelone 
and MCS were together in another quadrant. However, MCS + 
licofelone tended to approach the quadrant where Sham and 
licofelone were allocated. SPAs compared the miRNA expression 
in licofelone-treated mice versus sham-exposed mice (Figure 
3A), MCS-exposed mice versus sham-exposed mice (Figure 3B), 
and MCS-exposed mice, in the absence of the drug, versus MCS-
exposed mice treated with licofelone (Figure 3C). The symbols 
falling outside the diagonal belts refer to those miRNAs that 
varied at least 2-fold, either in the sense of upregulation or of 
downregulation, in the compared groups.
Volcano-plot analyses confirmed that 40 miRNAs (3.5%) 
changed their expression more than 2-fold and above the statis-
tical significance threshold (P < 0.05) in smoke-free mice treated 
with licofelone (Figure 3D). Twenty-six of them were upregulated 
and 14 were downregulated by the drug. A list of the licofelone-
dysregulated miRNAs, along with the fold-variation compared 
with sham-exposed mice, the statistical significance P value, 
and their main function(s), is reported in Supplementary Table 
S2, available at Carcinogenesis Online.
As shown in Figure 3B, exposure to MCS, in the absence of 
licofelone, mainly affected miRNAs expressed at high levels of 
intensity (upper right part of the expression cloud, red color 
dots). Volcano-plot analyses (Figure 3E) revealed that 62 miRNAs 
out of the 1135 tested (5.5%) were significantly downregulated 
Figure 1. Examples of 32P autoradiographs obtained by testing the lung DNA 
from mice, either unexposed (Sham) or exposed to MCS and treated with 
licofelone. The framed areas correspond to the DRZ in MCS-exposed mice where 
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by MCS (Supplementary Table S3 is available at Carcinogenesis 
Online). Licofelone was poorly effective in changing miRNA ex-
pression as compared with MCS alone (Figure 3C). In particular, 
volcano-plot analyses (Figure 3F) showed that licofelone was 
able to restore the expression of 7 of the 62 MCS-dysregulated 
miRNAs (11.3%). A  list of these miRNAs, all of which were 
upregulated by licofelone in MCS-exposed mice, is shown in 
Supplementary Table S4, available at Carcinogenesis Online.
Validation of microarray data by qPCR for miR-30b (Figure 
4) confirmed that this miRNA was upregulated by licofelone 
when compared with sham (Licofelone/Sham fold variation of 
1.7 by qPCR and 3.1 by microarray). Licofelone was effective in 
contrasting the downregulation of this miRNA in MCS-exposed 
mice by normalizing its expression (MCS + Licofelone/Sham fold 
variation of 1.1 by qPCR and 1.3 by microarray).
Discussion
The results of the present study provide evidence that licofelone 
succeeded in attenuating the formation of bulky DNA adducts 
and oxidative DNA damage in the lung of MCS-exposed mice. 
In addition, the drug was able to modulate the expression of 
several miRNAs in the lung of mice, either smoke-free or ex-
posed to MCS. Since the mice were exposed to MCS short after 
birth and received dietary licofelone for 6 weeks after weaning, 
the protocol that we used mimics a subchronic pharmacological 
treatment in current smokers. The 10-week period of exposure 
of mice to MCS covered the immediate post-natal time, during 
which the sudden transition from the maternal-mediated 
respiration to the autonomous pulmonary respiration causes 
paraphysiological genomic alterations in the lung (35), followed 
by the lactation period until completion of weaning. This period 
partially overlaps with adolescence, which in mice has been div-
ided into 3 ages, including pre-adolescence (23–35 days), mid-
adolescence (36–48 days) and post-adolescence (49–61 days) (36), 
leading to sexual maturity and early adulthood. Mice are con-
sidered to be adults after 2  months (8.6 weeks). The adminis-
tered dose of licofelone (960 mg/kg diet) was rather high, but it 
did neither affect survival nor body weight gain in smoke-free 
mice, which is in agreement with the results of a preliminary 
6-week subchronic toxicity study using post-weanling mice 
under the same experimental conditions (19). Even more, in the 
present study, licofelone exerted some protective effects against 
the small but significant loss of body weight gain induced by 
MCS 3–6 weeks after weanling. It should be also taken in mind 
that, while licofelone is administered once or twice per day in 
humans, the intake of the drug in mice with the diet is highly 
fractionated because rodents eat continuously depending on 
their metabolic needs, which is expected to result in a greater 
tolerability. However, as shown in the part of the present study 
evaluating modulation of systemic genotoxicity and in the par-
allel cancer chemoprevention study (19), licofelone exhibited 
some signs of toxicity, in terms of a decrease in survival and 
body weight gain, when it was administered for more than 
4 months to MCS-exposed mice.
In agreement with the results of previous studies (21,22,37–
41), exposure of mice to MCS resulted in an evident oxidative 
DNA damage in lung. Moreover, high levels of bulky DNA ad-
ducts were detectable in the form of DRZ at 32P postlabeling, 
which is typical for exposure to complex mixtures. MCS-
induced DNA alterations were of the same order of magnitude 
in male and female mice. As shown in mice exposed to CS, oxi-
dative stress and the resulting DNA damage provide a major 
contribution to the high susceptibility of mice exposed early 
in life (42). Administration of licofelone to MCS-exposed mice 
approximately halved DNA adduct levels in both genders by 
mainly inhibiting slowly migrating components of DRZ. These 
include lipophilic bulky adducts resulting from DNA adduction 
with polycyclic aromatic hydrocarbons and lipid peroxide me-
tabolites. Even greater (about three times) was inhibition of oxi-
dative DNA damage in the lung of MCS-exposed mice, to such 
an extent that 8-oxo-dGuo levels in MCS-exposed mice treated 
with licofelone were reverted to the same levels observed in 
sham-exposed mice.
On the other hand, administration of licofelone caused a 
slight but statistically significant increase in MN NCE frequency 
Table 1. Bulky DNA adducts and 8-oxo-dGuo levels in the lung of 40 mice aged 10 weeks as related to gender, exposure to MCS since birth and/






Sham Males 1.31 ± 0.17 1.70 ± 0.22
 Females 1.23 ± 0.15 2.11 ± 0.18
Licofelone Males 0.93 ± 0.17 1.90 ± 0.27
 Females 1.13 ± 0.18 2.06 ± 0.26
MCS Males 17.92 ± 1.77a 5.03 ± 0.08a
 Females 20.04 ± 2.95a 5.97 ± 0.44a
MCS + licofelone Males 8.40 ± 0.79a,c 1.67 ± 0.07d
 Females 10.16 ± 1.53a,b 2.11 ± 0.25d
The results are means ± SE within each group of 5 mice. Statistical analysis: aP < 0.001, as compared with sham-exposed mice of the same gender; bP < 0.05, cP < 0.01, 
and dP < 0.001, as compared with MCS-exposed mice of the same gender.
Table 2. Frequency of MN NCE in the peripheral blood of 60 Swiss H 
mice aged 4 months, immediately after discontinuation of exposure 





MN NCE (‰) 
Mean ± SE
Sham 0 M 1.33 ± 0.098
 0 F 0.86 ± 0.082
MCS 0 M 1.93 ± 0.139a
 0 F 1.18 ± 0.059a
MCS + 960 M 2.85 ± 0.193b,c
Licofelone 960 F 1.57 ± 0.103b,c
Each experimental group was composed of 10 mice/gender; 50,000 NCE were 
examined in each mouse. Statistical analysis: aP < 0.01 and bP < 0.001, as com-
pared with sham-exposed mice of the same gender. cP < 0.01, as compared with 
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Figure 3. (A–C) Scatter-plot analyses comparing the expression of pulmonary miRNAs in sham-exposed mice vs. mice treated with licofelone (A), MCS-exposed mice vs. 
sham-exposed mice (B), and MCS-exposed mice treated with licofelone versus MCS-exposed mice in the absence of the drug (C). Each dot represents a miRNA, whose ex-
pression intensity can be inferred from the position in the x and y axes, according to a color scale (blue, low; yellow, medium; orange to red, high). The diagonal belts indicate 
the 2-fold variation interval. Symbols falling in the upper area denote miRNA upregulation, and those falling in the lower area denote miRNA downregulation by licofelone. 
(D–F) Volcano-plot analyses comparing the expression of pulmonary miRNAs in sham-exposed mice versus mice treated with licofelone (D), MCS-exposed mice versus 
sham-exposed mice (E), and MCS-exposed mice treated with licofelone versus MCS-exposed mice in the absence of the drug (F). The two green vertical lines indicate the 
2-fold variation interval, and the horizontal green line indicates the P < 0.05 threshold. miRNAs falling outside these intervals are highlighted in red color.
Figure 2. Global expression of 1135 pulmonary miRNAs in the mice belonging to 4 experimental groups, including sham-exposed mice, mice receiving licofelone with the 
diet for 6 weeks, starting after weanling, and mice exposed to MCS for 10 weeks, starting after birth, either untreated or treated with licofelone. (A) Hierarchical cluster ana-
lysis (HCA). Within each column, the expression of the analyzed lung miRNAs is represented on a relative color scale (blue, low; yellow, medium; orange to red, high). (B) 
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in the mice aged 4  months, as compared with MCS-exposed 
mice in the absence of chemopreventive agent. This finding 
was unexpected but consistent in both males and females. At 
that time, as previously mentioned, MCS-exposed mice treated 
with licofelone underwent a further decrease in survival and 
body weight gain as compared with mice exposed to MCS in the 
absence of chemopreventive treatment. Therefore, such an en-
hancement of systemic genotoxicity may reflect some toxicity 
of the drug after a longer administration to MCS-exposed mice. 
Targeting upstream enzymes affects multiple downstream 
pathways and may produce adverse effects by disrupting the 
balance between different AA-metabolizing pathways (43). 
Presumably, the simultaneous inhibition by licofelone of the 
COX-1/2 and 5-LOX pathways may shunt the metabolism of 
AA via the CYP pathway thereby favoring the formation of free 
radical products and modulating the metabolism of carcino-
gens contained in MCS (44).
Even after 6 weeks only, administration of licofelone to 
smoke-free mice caused an extensive dysregulation of pul-
monary miRNAs, which may underlie the occurrence of ei-
ther protective mechanisms and/or possible alterations of the 
physiological homeostasis. In particular, out of 40 miRNAs 
dysregulated by licofelone, 26 were upregulated and 14 were 
downregulated. The emerging picture is rather intricate, also 
because miRNAs possess pleiomorphic properties and regulate 
a number of genes simultaneously, a single miRNA targeting 
approximately 200 transcripts (45). The miRNAs modulated 
by dietary licofelone in mouse lung included miRNAs that are 
mainly involved in inflammation (miR-125b, miR-146a, miR-147, 
miR-149, miR-574), stress response (miR-30b, miR-146a, miR-
342), cell proliferation (let-7f, miR-1a, miR-362, miR-466h, miR-
574, miR-1224, miR-3064), apoptosis (miR-1a, miR-98, miR-149, 
miR-204, miR-574, miR-700), cell adhesion (let-7c, miR-30b, miR-
135b, miR-205, miR-592), cell differentiation (miR-143, miR-204, 
miR-363, miR-705), angiogenesis (let-7f, miR-98, miR-205, miR-
592), regulation of k-Ras (let-7f, miR-135b, miR-143, miR-466h) 
or other oncogenes (miR-98, miR-125b, miR-149, miR-381, miR-
542, miR-744), and modulation of suppressor genes (miR-190a, 
miR-1224).
Two miRNAs involved in cardiovascular development (miR-
3065) and in the regulation of cardiac hyperthrophy (miR-672) 
were also upregulated by licofelone. miR-672 showed suppres-
sive effects on cardiac hypertrophy through regulating the ex-
pression of Jun in cardiomyocytes (46). As mentioned in the 
Introduction, targeting both COX and 5-LOX pathways may 
avoid cardiovascular side effects (17), and 5-LOX has been iden-
tified as a major gene contributing to atherosclerosis suscep-
tibility in mice (47). The only miRNA upregulated by licofelone 
that is involved in COX-2 regulation was miR-146a. This miRNA 
is downregulated in lung cancer cells thereby increasing COX-2 
expression and the related inflammation (48). The fact that one 
only of the 40 licofelone-modulated miRNAs targeted COX-2 
suggests that COX-2 inhibition by licofelone is exerted by direct 
interaction with the enzyme and not by epigenetic modulation.
In line with previous studies (22,39–41,49–55), exposure 
of mice to MCS resulted in an extensive dysregulation of 
pulmonary miRNAs, which was oriented in the sense of 
downregulation. The reliability of microarrays for evaluating 
miRNA dysregulation in the lung of MCS-exposed mice was 
validated by means of qPCR analyses in the present study and 
in several previous studies investigating the effects of MCS 
and other putative chemopreventive agents (vorinostat, myo-
inositol, bexarotene, pioglitazone, metformin, lapatinib, as-
pirin, naproxen, and celecoxib) under experimental conditions 
similar to those used in the present study (22,39–41,49,54,55). 
The 62 miRNAs downregulated by MCS in the present study 
are involved in a variety of functions, mainly including onco-
gene inhibition, stress response, apoptosis and angiogenesis. 
These findings underlie the fact that epigenomic alterations 
overwhelm genomic alterations in MCS-related pulmonary 
carcinogenesis. Indeed, in a separate study we explored onco-
gene k-ras hotspot mutations by pyrosequencing in the lung of 
cancer-free mice, either sham-exposed or exposed to MCS for 
10 weeks. As assessed in two separate laboratories, no mutation 
(G→ T transversion, codon 12/13) was detected in any of the 20 
mice examined (Izzotti et  al., manuscript in preparation). The 
observed lack of mutation of k-ras in MCS-exposed mice is con-
sistent with Cosmic data (https://cancer.sanger.ac.uk/cosmic) 
reporting that, in human full blown lung cancer, k-ras mutation 
frequency is 16% only.
In MCS-exposed mice, licofelone upregulated 7 miRNAs, 
thus restoring their expression that had been downregulated 
Figure 4. Evaluation of miR-30b expression by qPCR. Amplification curves are reported for each one of the four experimental conditions. The column graph quantifies 
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by MCS exposure. The expression of 3 of these miRNAs (miR-
30b, miR-125b, miR-466h) was also upregulated by licofelone in 
smoke-free mice. Interestingly, a homologue of miR-30b (miR-
30e) and two homologues of miR-466h (miR-466a and miR-466i) 
had been found to be significantly less expressed in the lungs of 
adenoma-bearing as compared with adenoma-free 7.5-month-
old Swiss albino mice exposed to MCS during the first 4 months 
of life and treated with the nonselective COX-1/COX-2 inhibitor 
aspirin after weaning (22). These findings suggest that these 
miRNAs play a protective role in MCS-related carcinogenesis 
since they were more abundant in the lung of adenoma-free 
mice than in the lung of adenoma-bearing mice sharing ex-
posure to MCS. A  similar situation occurred in mice treated 
with the other nonselective NSAID naproxen, in which another 
miR-30b homologue (miR-30c) was significantly more expressed 
in MCS-exposed mice treated with the drug that were free of 
adenomas than in those bearing adenomas (22). On the other 
hand, the miRNAs upregulated by the selective COX-2 inhibitor 
celecoxib in the lung of MCS-exposed Swiss H mice were dif-
ferent from those upregulated by licofelone under identical ex-
perimental conditions (21). As to miR-125b, this miRNA having 
multiple functions was upregulated both in the lung of Swiss 
H mice exposed for 10 weeks to MCS since birth and treated 
with licofelone after weaning (present study) and in the lung 
of 2-month old ICR(CD-1) mice exposed to MCS for 8 weeks and 
receiving celecoxib during the same period (21).
The experimental model used in the present study is suitable 
to evaluate the protective effects of a putative chemopreventive 
agent towards MCS, which is the most important human car-
cinogen. At the same time, such a methodological approach 
is also suitable to evaluate possible adverse effects because 
the drug is tested not only in in MCS-exposed mice but also 
in smoke-free mice. In principle, the ability of a given agent 
to counteract the DNA and RNA alterations induced by MCS 
may be assumed as a molecular indicator of efficacy, whereas 
a poor disturbance of DNA and RNA physiological expressions 
in smoke-free mice may be assumed as a molecular indicator 
of safety.
In this light, licofelone exerted convincing protective effects 
towards MCS but, at the same dose, it produced some interfer-
ence with the physiological molecular machinery in smoke-free 
mice. Both trends correlated with the modulation of patho-
logical alterations resulting from exposure to MCS and/or treat-
ment with this NSAID. In particular, at a dose and treatment 
time (6 weeks) that did not produce any sufferance or body loss 
in mice but, on the contrary, it protected the mice from the MCS-
induced body weight loss, dietary licofelone caused an early 
inhibition of oxidative DNA damage and bulky DNA adducts in-
duced by MCS in mouse lung. This was accompanied by modu-
lation of the expression of miRNAs involved in inflammation, 
stress response and other protective functions. Such an outcome 
is consistent with the known anti-inflammatory properties of 
this NSAIDS and correlates with the finding that, in the medium 
term (7.5  months), licofelone protected the mice from MCS-
induced pulmonary emphysema, bronchial epithelial hyper-
plasia, and it attenuated the formation of lung microadenomas, 
which are probably related to MCS-related chronic inflamma-
tion (19). Microadenomas are larger than hyperplastic foci, tend 
to regress spontaneously (56), and do not necessarily contribute 
to the development of lung tumors (40). In addition, consist-
ently with the notions that chronic inflammation plays a key 
role in all stages of the carcinogenesis process (8) and that the 
COX-2/PGE2 signaling pathway is involved in the development 
of malignant cells (57), the yield of malignant tumors in the 
lungs of MCS-exposed mice treated with licofelone was lower 
when compared with MCS-exposed mice that did not receive 
the drug (19). This finding is in agreement with the conclusions 
of another study, in which licofelone administration attenuated 
the benzo(a)pyrene-induced yield of lung tumors in mice after 
that dysplasia had already developed (28). In the direct com-
parison of licofelone with celecoxib, the former NSAIDS showed 
in general better protective effects (40), consistently with the 
assumption that triple inhibitors that block COX-1, COX-2 and 
5-LOX may provide synergistic anti-inflammatory effects com-
pared with COX inhibitors (23). On the other hand, administra-
tion of licofelone to smoke-free mice, even in the short term, 
resulted in a broad dysregulation of pulmonary miRNAs, some 
of which may trigger adverse effects. In addition, after 4 months 
licofelone slightly but significantly enhanced the MCS-related 
systemic genotoxicity (present study) and, after that time, ad-
ministration of licofelone to MCS-exposed mice worsened sur-
vival and body weight gain (19).
In conclusion, the results of the present study provide evi-
dence that evaluation of early genomic and epigenetic end-
points highlights the ability of licofelone to counteract certain 
mechanisms involved in the pathogenesis of cancer and other 
chronic degenerative diseases, thus explaining the previously 
observed cancer protective effects. In the long term, how-
ever, the licofelone dose used also exhibited some toxic ef-
fects. Therefore, caution should be paid when administering 
licofelone to smokers.
Supplementary material
Supplementary data are available at Carcinogenesis online.
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